Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Equity Average (2020 - 2025)

Xeris Biopharma Holdings' Equity Average history spans 6 years, with the latest figure at $6.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 122.14% year-over-year to $6.4 million, compared with a TTM value of $6.4 million through Dec 2025, up 122.14%, and an annual FY2025 reading of -$8.0 million, up 56.24% over the prior year.
  • Equity Average for Q4 2025 was $6.4 million at Xeris Biopharma Holdings, up from -$10.1 million in the prior quarter.
  • The five-year high for Equity Average was $95.8 million in Q1 2022, with the low at -$32.4 million in Q1 2025.
  • Average Equity Average over 5 years is $17.5 million, with a median of $8.7 million recorded in 2021.
  • Year-over-year, Equity Average skyrocketed 640.13% in 2022 and then tumbled 1886.22% in 2024.
  • Tracing XERS's Equity Average over 5 years: stood at $46.4 million in 2021, then grew by 8.04% to $50.1 million in 2022, then tumbled by 102.91% to -$1.5 million in 2023, then tumbled by 1886.22% to -$29.0 million in 2024, then surged by 122.14% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Equity Average are $6.4 million (Q4 2025), -$10.1 million (Q3 2025), and -$27.2 million (Q2 2025).